Neuroanatomical predictors of response to donepezil therapy in patients with dementia

被引:39
作者
Csernansky, JG
Wang, L
Miller, JP
Galvin, JE
Morris, JC
机构
[1] Washington Univ, Sch Med, Dept Psychiat, Alzheimers Dis Res Ctr, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
关键词
D O I
10.1001/archneur.62.11.1718
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Patients with dementia of the Alzheimer type (DAT) respond variably to treatment with acetylcholinesterase inhibitors. Objective: To determine whether measures of hippocampal volume and shape predict the response to donepezil in patients with DAT. Design: T1-weighted, magnetic resonance images were obtained from patients with DAT, who subsequently underwent treatment with donepezil. Brain-mapping algorithms were used to quantify hippocampal volume and shape, and growth curves were used to estimate clinical outcome. Setting: A referral outpatient center specializing in treatment of dementia. Patients: Thirty-seven patients with very mild or mild DAT received donepezil therapy for up to 4 weeks be-fore magnetic resonance imaging and for 24 to 96 weeks after magnetic resonance imaging. Intervention: Donepezil, 10 mg/d. Main Outcome Measure: Rate of change in- the cognitive portion of the Alzheimer's Disease Assessment Scale total scores. Results: Smaller hippocampal volume and inward variation of the lateral and inferomedial portions of the hippocampal surface were correlated with a poorer response to donepezil therapy. Conclusions: Measures of hippocampal volume and surface variation can be used to predict the response of patients with DAT to the acetylcholinesterase inhibitor donepezil.
引用
收藏
页码:1718 / 1722
页数:5
相关论文
共 24 条
[1]   Computer-assisted imaging to assess brain structure in healthy and diseased brains [J].
Ashburner, J ;
Csernansky, JG ;
Davatzikos, C ;
Fox, NC ;
Frisoni, GB ;
Thompson, PM .
LANCET NEUROLOGY, 2003, 2 (02) :79-88
[2]   MILD SENILE DEMENTIA OF THE ALZHEIMER TYPE .4. EVALUATION OF INTERVENTION [J].
BERG, L ;
MILLER, JP ;
BATY, J ;
RUBIN, EH ;
MORRIS, JC ;
FIGIEL, G .
ANNALS OF NEUROLOGY, 1992, 31 (03) :242-249
[3]   NEUROPATHOLOGICAL INDEXES OF ALZHEIMERS-DISEASE IN DEMENTED AND NONDEMENTED PERSONS AGED 80 YEARS AND OLDER [J].
BERG, L ;
MCKEEL, DW ;
MILLER, JP ;
BATY, J ;
MORRIS, JC .
ARCHIVES OF NEUROLOGY, 1993, 50 (04) :349-358
[4]   Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly [J].
Csernansky, JG ;
Wang, L ;
Swank, J ;
Miller, JP ;
Gado, M ;
McKeel, D ;
Miller, M ;
Morriss, JC .
NEUROIMAGE, 2005, 25 (03) :783-792
[5]   Hippocampal structure and the action of cholinomimetic drugs [J].
Csernansky, JG ;
Bardgett, ME ;
Dong, HX ;
Humphrey, W ;
Wang, L .
DRUG DEVELOPMENT RESEARCH, 2002, 56 (03) :531-540
[6]   THE NEUROPSYCHIATRIC INVENTORY - COMPREHENSIVE ASSESSMENT OF PSYCHOPATHOLOGY IN DEMENTIA [J].
CUMMINGS, JL ;
MEGA, M ;
GRAY, K ;
ROSENBERGTHOMPSON, S ;
CARUSI, DA ;
GORNBEIN, J .
NEUROLOGY, 1994, 44 (12) :2308-2314
[7]   Drug therapy - Alzheimer's disease [J].
Cummings, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (01) :56-67
[8]   Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease [J].
Farlow, MR ;
Lahiri, DK ;
Poirier, J ;
Davignon, J ;
Schneider, L ;
Hui, SL .
NEUROLOGY, 1998, 50 (03) :669-677
[9]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[10]   Three-dimensional hippocampal MR morphometry with high-dimensional transformation of a neuroanatomic atlas [J].
Haller, JW ;
Banerjee, A ;
Christensen, GE ;
Gado, M ;
Joshi, S ;
Miller, MI ;
Sheline, Y ;
Vannier, MW ;
Csernansky, JG .
RADIOLOGY, 1997, 202 (02) :504-510